Financial reports
10-Q
2024 Q1
Quarterly report
1 Feb 24
10-K
2023 FY
Annual report
13 Nov 23
10-Q
2023 Q3
Quarterly report
2 Aug 23
10-Q
2023 Q2
Quarterly report
4 May 23
10-Q
2023 FY
Quarterly report
6 Feb 23
10-K
2022 FY
Annual report
14 Nov 22
10-Q
2022 Q3
Quarterly report
3 Aug 22
10-Q
2022 Q2
Quarterly report
4 May 22
10-Q
2022 Q1
Quarterly report
3 Feb 22
10-K
2021 FY
Annual report
16 Nov 21
Current reports
8-K
Submission of Matters to a Vote of Security Holders
5 Mar 24
8-K
Oaktree Specialty Lending Corporation Announces First Fiscal Quarter 2024 Financial Results and Declares Quarterly Distribution of $0.55 Per Share
1 Feb 24
8-K
Oaktree Specialty Lending Corporation Announces Fourth Fiscal Quarter and Full Year 2023
14 Nov 23
8-K
Entry into a Material Definitive Agreement
15 Aug 23
8-K
Entry into a Material Definitive Agreement
9 Aug 23
8-K
Entry into a Material Definitive Agreement
8 Aug 23
8-K
Oaktree Specialty Lending Corporation Announces Third Fiscal Quarter 2023 Financial Results
3 Aug 23
8-K
Entry into a Material Definitive Agreement
26 Jun 23
8-K
Entry into a Material Definitive Agreement
30 May 23
8-K
Oaktree Specialty Lending Corporation Announces Second Fiscal Quarter 2023 Financial
4 May 23
Registration and prospectus
424B2
Prospectus for primary offering
10 Aug 23
FWP
Free writing prospectus
8 Aug 23
424B5
Prospectus supplement for primary offering
8 Aug 23
424B2
Prospectus for primary offering
8 Aug 23
424B2
Prospectus for primary offering
8 Feb 23
POS EX
Additional exhibits for listing
23 Jan 23
425
Business combination disclosure
10 Jan 23
425
Business combination disclosure
2 Dec 22
424B3
Prospectus supplement
30 Nov 22
N-14 8C/A
Registration statement for closed-end investment company (amended)
28 Nov 22
Proxies
DEFA14A
Additional proxy soliciting materials
30 Jan 24
DEF 14A
Definitive proxy
22 Jan 24
DEFA14A
Additional proxy soliciting materials
19 Jan 24
DEFA14A
Additional proxy soliciting materials
10 Jan 24
DEF 14A
Definitive proxy
10 Jan 24
PRE 14A
Preliminary proxy
21 Dec 23
DEFA14A
Additional proxy soliciting materials
6 Mar 23
DEFA14A
Additional proxy soliciting materials
6 Feb 23
DEF 14A
Definitive proxy
6 Feb 23
PRE 14A
Preliminary proxy
24 Jan 23
Other
EFFECT
Notice of effectiveness
1 Dec 22
EFFECT
Notice of effectiveness
22 Jan 21
CORRESP
Correspondence with SEC
19 Jan 21
EFFECT
Notice of effectiveness
14 Jan 20
CORRESP
Correspondence with SEC
9 Jan 20
CORRESP
Correspondence with SEC
9 Jan 20
CORRESP
Correspondence with SEC
24 Jul 17
CORRESP
Correspondence with SEC
21 Feb 17
CORRESP
Correspondence with SEC
21 Feb 17
CORRESP
Correspondence with SEC
18 Jan 17
Ownership
4
PHYLLIS R CALDWELL
14 Feb 24
4
IMPEL PHARMACEUTICALS INC
4 Dec 23
3
IMPEL PHARMACEUTICALS INC
20 Nov 23
SC 13D/A
OAKTREE CAPITAL MANAGEMENT LP
7 Aug 23
SC 13D/A
OAKTREE CAPITAL MANAGEMENT LP
1 Aug 23
4
Ashley Pak
12 Apr 23
4
Matthew Stewart
27 Mar 23
4
Christopher McKown
20 Mar 23
4
PHYLLIS R CALDWELL
20 Mar 23
4
Mathew Pendo
13 Feb 23